Logo image of CTSO

CYTOSORBENTS CORP (CTSO) Stock Fundamental Analysis

USA - NASDAQ:CTSO - US23283X2062 - Common Stock

0.6655 USD
+0.03 (+4.16%)
Last: 11/13/2025, 8:00:01 PM
0.72 USD
+0.05 (+8.19%)
After Hours: 11/13/2025, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, CTSO scores 2 out of 10 in our fundamental rating. CTSO was compared to 189 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of CTSO have multiple concerns. CTSO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CTSO has reported negative net income.
In the past year CTSO has reported a negative cash flow from operations.
CTSO had negative earnings in each of the past 5 years.
CTSO had a negative operating cash flow in each of the past 5 years.
CTSO Yearly Net Income VS EBIT VS OCF VS FCFCTSO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

CTSO's Return On Assets of -20.32% is in line compared to the rest of the industry. CTSO outperforms 50.79% of its industry peers.
CTSO has a Return On Equity of -84.15%. This is in the lower half of the industry: CTSO underperforms 61.38% of its industry peers.
Industry RankSector Rank
ROA -20.32%
ROE -84.15%
ROIC N/A
ROA(3y)-50.29%
ROA(5y)-37.4%
ROE(3y)-134.62%
ROE(5y)-90.6%
ROIC(3y)N/A
ROIC(5y)N/A
CTSO Yearly ROA, ROE, ROICCTSO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

CTSO has a better Gross Margin (73.19%) than 84.13% of its industry peers.
CTSO's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for CTSO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.74%
GM growth 5Y0.03%
CTSO Yearly Profit, Operating, Gross MarginsCTSO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

2

2. Health

2.1 Basic Checks

CTSO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CTSO has been increased compared to 1 year ago.
CTSO has more shares outstanding than it did 5 years ago.
CTSO has a worse debt/assets ratio than last year.
CTSO Yearly Shares OutstandingCTSO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CTSO Yearly Total Debt VS Total AssetsCTSO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -8.24, we must say that CTSO is in the distress zone and has some risk of bankruptcy.
CTSO's Altman-Z score of -8.24 is on the low side compared to the rest of the industry. CTSO is outperformed by 74.07% of its industry peers.
A Debt/Equity ratio of 1.24 is on the high side and indicates that CTSO has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.24, CTSO is doing worse than 78.31% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.24
Debt/FCF N/A
Altman-Z -8.24
ROIC/WACCN/A
WACC9.09%
CTSO Yearly LT Debt VS Equity VS FCFCTSO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 2.34 indicates that CTSO has no problem at all paying its short term obligations.
CTSO's Current ratio of 2.34 is in line compared to the rest of the industry. CTSO outperforms 44.44% of its industry peers.
CTSO has a Quick Ratio of 1.96. This is a normal value and indicates that CTSO is financially healthy and should not expect problems in meeting its short term obligations.
CTSO's Quick ratio of 1.96 is in line compared to the rest of the industry. CTSO outperforms 52.38% of its industry peers.
Industry RankSector Rank
Current Ratio 2.34
Quick Ratio 1.96
CTSO Yearly Current Assets VS Current LiabilitesCTSO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

CTSO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.52%, which is quite impressive.
The Revenue has decreased by -7.81% in the past year.
The Revenue has been growing slightly by 7.36% on average over the past years.
EPS 1Y (TTM)68.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%137.5%
Revenue 1Y (TTM)-7.81%
Revenue growth 3Y-6.23%
Revenue growth 5Y7.36%
Sales Q2Q%-2.81%

3.2 Future

Based on estimates for the next years, CTSO will show a very strong growth in Earnings Per Share. The EPS will grow by 25.71% on average per year.
Based on estimates for the next years, CTSO will show a very strong growth in Revenue. The Revenue will grow by 27.36% on average per year.
EPS Next Y58.39%
EPS Next 2Y30.57%
EPS Next 3Y25.71%
EPS Next 5YN/A
Revenue Next Year0.37%
Revenue Next 2Y10.3%
Revenue Next 3Y16.54%
Revenue Next 5Y27.36%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CTSO Yearly Revenue VS EstimatesCTSO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
CTSO Yearly EPS VS EstimatesCTSO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CTSO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CTSO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTSO Price Earnings VS Forward Price EarningsCTSO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTSO Per share dataCTSO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4

4.3 Compensation for Growth

CTSO's earnings are expected to grow with 25.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.57%
EPS Next 3Y25.71%

More info and screens

0

5. Dividend

5.1 Amount

CTSO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYTOSORBENTS CORP

NASDAQ:CTSO (11/13/2025, 8:00:01 PM)

After market: 0.72 +0.05 (+8.19%)

0.6655

+0.03 (+4.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-13 2025-11-13/amc
Inst Owners26.47%
Inst Owner Change-2.48%
Ins Owners9.06%
Ins Owner Change1.46%
Market Cap41.77M
Revenue(TTM)34.26M
Net Income(TTM)-9.75M
Analysts80
Price Target5.1 (666.34%)
Short Float %2.48%
Short Ratio13.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)115.41%
Min EPS beat(2)71.99%
Max EPS beat(2)158.82%
EPS beat(4)3
Avg EPS beat(4)38.04%
Min EPS beat(4)-116.73%
Max EPS beat(4)158.82%
EPS beat(8)6
Avg EPS beat(8)16.47%
EPS beat(12)7
Avg EPS beat(12)8.26%
EPS beat(16)7
Avg EPS beat(16)-8.03%
Revenue beat(2)1
Avg Revenue beat(2)-1.45%
Min Revenue beat(2)-5.01%
Max Revenue beat(2)2.1%
Revenue beat(4)1
Avg Revenue beat(4)-5.92%
Min Revenue beat(4)-11.18%
Max Revenue beat(4)2.1%
Revenue beat(8)2
Avg Revenue beat(8)-5.09%
Revenue beat(12)4
Avg Revenue beat(12)-4.73%
Revenue beat(16)5
Avg Revenue beat(16)-5.68%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.71%
EPS NY rev (1m)0%
EPS NY rev (3m)1.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.22
P/FCF N/A
P/OCF N/A
P/B 3.6
P/tB 5.32
EV/EBITDA N/A
EPS(TTM)-0.17
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0.55
BVpS0.18
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.32%
ROE -84.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.19%
FCFM N/A
ROA(3y)-50.29%
ROA(5y)-37.4%
ROE(3y)-134.62%
ROE(5y)-90.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.74%
GM growth 5Y0.03%
F-Score4
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 1.24
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.58%
Cap/Sales 1.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.34
Quick Ratio 1.96
Altman-Z -8.24
F-Score4
WACC9.09%
ROIC/WACCN/A
Cap/Depr(3y)278.83%
Cap/Depr(5y)335.47%
Cap/Sales(3y)7.84%
Cap/Sales(5y)7.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%137.5%
EPS Next Y58.39%
EPS Next 2Y30.57%
EPS Next 3Y25.71%
EPS Next 5YN/A
Revenue 1Y (TTM)-7.81%
Revenue growth 3Y-6.23%
Revenue growth 5Y7.36%
Sales Q2Q%-2.81%
Revenue Next Year0.37%
Revenue Next 2Y10.3%
Revenue Next 3Y16.54%
Revenue Next 5Y27.36%
EBIT growth 1Y34.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.7%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.77%
OCF growth 3YN/A
OCF growth 5YN/A

CYTOSORBENTS CORP / CTSO FAQ

What is the fundamental rating for CTSO stock?

ChartMill assigns a fundamental rating of 2 / 10 to CTSO.


What is the valuation status for CTSO stock?

ChartMill assigns a valuation rating of 1 / 10 to CYTOSORBENTS CORP (CTSO). This can be considered as Overvalued.


How profitable is CYTOSORBENTS CORP (CTSO) stock?

CYTOSORBENTS CORP (CTSO) has a profitability rating of 1 / 10.


What is the financial health of CYTOSORBENTS CORP (CTSO) stock?

The financial health rating of CYTOSORBENTS CORP (CTSO) is 2 / 10.